Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ENTA
ENANTA PHARMACEUTICALS, INC.
NASDAQ
$13.60
▼ DOWN 1.45% (-0.20)

KEY STATISTICS

Market Cap$395.47 M
52w High$17.15
52w Low$7.05
Dividend Yield—
Frequency—
P/E-5.64
Volume155.91K
Shares Out.29.08M

COMPANY

LEADERSHIP

Jay R. Luly
CHIEF EXECUTIVE
Jay R. Luly

COMPENSATION 2026

Salary$803,300
Stock Awards$128,550
Incentive Plan Pay$591,665
All Other Comp.$22,058
Total$2,769,548

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 21, 2013
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
120

PRICE TARGET

Target High$20.00
Target Low$20.00
Target Median$20.00
Target Consensus$20.00

UPCOMING EARNINGS

DateNov 16, 2026
DayMonday
Rev. Est.$15.70M
NOV
16
MON

PRICE

$13.60 ▼ DOWN 1.45% (−$0.20)
$13.50$13.65$13.809:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM13.60

About Enanta Pharmaceuticals, Inc.

https://www.enanta.com ↗

Enanta Pharmaceuticals, founded in 1995 in Watertown, MA, develops small molecule drugs for viral infections and liver diseases, including collaborations with Abbott on hepatitis C treatments.

INDUSTRY

Biotechnology

A PRODUCT ENANTA PHARMACEUTICALS, INC. IS KNOWN FOR

Zelicapavir (EDP-938)
Zelicapavir (EDP-938)

Zelicapavir is an investigational oral N-protein inhibitor for RSV, showing positive Phase 2b results and advancing toward potential Phase 3, making it Enanta's leading candidate in their RSV development portfolio.

COMPETITORS

COMPETITOR
GSK COMPARE
MRK COMPARE
MRNA COMPARE
PFE COMPARE
SNY COMPARE

Revenue by Products

IconPRODUCTQ4-2025Q1-2026Q2-2026Q3-2026
Royalty$15.13M $18.61M ▲$17.16M ▼$14.36M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
88
LISTED HERE
16
RANKED BY POSITION SIZE
VTS.AX
0.00% · 877.1K
XSU.TO
0.01% · 726.3K
SCHA
0.01% · 127.3K
DFAS
0.01% · 62.3K
R2US.L
0.01% · 56.3K
SBIO
0.20% · 36.0K
PRFZ
0.02% · 34.9K
XRS2.DE
0.01% · 26.0K
RSSL
0.01% · 13.5K
SILX
0.72% · 6.7K
GERM
0.62% · 4.6K
RFLR
0.04% · 2.7K
URTY
0.00% · 1.2K
DM
DMRS
0.05% · 531
FSEV
0.07% · 340
AVSU
0.00% · 62

INSTITUTIONAL OWNERSHIP

SHARES OWNED
85.92%
HOLDERS
220
TOP 12 OF 220 · RANKED BY POSITION SIZE
Janus Henderson Group Plc
3.8M sh · $47.72M
Blackrock, Inc.
3.2M sh · $47.3M
Farallon Capital Management LLC
2.9M sh · $36.27M
Krensavage Asset Management, LLC
2.9M sh · $41.79M
Vanguard Group Inc
2.3M sh · $36.3M
Deep Track Capital, LP
2.0M sh · $24.72M
Blackrock Inc.
1.8M sh · $23.96M
Blackrock Fund Advisors
1.4M sh · $48.48M
Adar1 Capital Management, LLC
1.3M sh · $19.6M
Apex Capital Management
1.3M sh · $37.97M
Acadian Asset Management LLC
1.1M sh · $15.71M
Millennium Management LLC
948.1K sh · $11.35M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book2
Overall Score1

TRADES BY CONGRESS

HOUSE TRADES
Daniel Goldman
Daniel Goldman
Sale
2023-07-12

INSIDER TRADES

★
OFFICER: CHIEF MEDICAL OFFICER
Rottinghaus Scott T.
Sale · 1.5K shares
2026-08-08
★
DIRECTOR
Vance Terry
Purchase · 20.0K shares
2026-03-11
★
DIRECTOR
Russell Lesley
Purchase · 20.0K shares
2026-03-11
★
DIRECTOR
Peterson Kristine
Purchase · 20.0K shares
2026-03-11

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OUTPERFORM 1
4 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Jefferies BUY WestPark Capital BUY Evercore ISI Group OUTPERFORM

SECTORS PEERS

PEERPRICE
ASMB$34.07COMPARE
PRLD$5.47COMPARE
AVIR$5.36COMPARE
FHTX$6.00COMPARE
VYGR$3.54COMPARE
PYXS$3.23COMPARE
IMRX$4.99COMPARE
CRBU$1.62COMPARE